Project Grant R56HL173197
Award Date
9/13/24
Completion Date
8/31/25
Dollars Obligated
$1.5M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Bronx, NY 10461, USA
Similar Awards
This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $161,922 to the Albert Einstein College of Medicine to elucidate the interplay between DDX41 and CUX1 mutations and their impact on hematopoiesis. The research will utilize zebrafish models and human induced pluripotent stem cells (iPSCs) to characterize changes in hematopoietic stem and progenitor cells, as well as differentiated progeny, under these...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $146,922 to the Albert Einstein College of Medicine in Bronx, NY to conduct research on "Deciphering Genotype-Environmental Interaction that Drives HSPC Dysfunction". The research aims to investigate how environmental factors interact with genetic mutations in the DDX41 gene to promote dysfunction in hematopoietic stem and...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $785,198 to the Albert Einstein College of Medicine in Bronx, NY to study the role of chaperone-mediated autophagy (CMA) in regulating cardiac fibroblast and myofibroblast function and its impact on heart repair following myocardial infarction. The research aims to investigate how CMA modulates the proteomic profile, phenotype, and function of reparative...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research provides $784,206 to investigate the role of the CSF-1/CSF-1R axis in myocardial infarction (MI) repair and remodeling. The award to Albert Einstein College of Medicine will fund research to: 1) examine the in vivo effects of macrophage-specific CSF-1R activation on cardiac repair and remodeling after MI; 2) investigate the role of fibroblast-derived CSF-1 in...
This federal Project Grant award for $657,368.00, issued by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the mechanisms controlling microRNA (miRNA) processing and degradation pathways during hematopoietic development. The primary awardee, The Washington University, will utilize human pluripotent stem cell lines with mutations in miRNA deadenylases and exosome components to identify novel...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $121,875 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to The Trustees of the University of Pennsylvania, doing business as Clinical Practices of the University of Pennsylvania, for the project "A MAP OF RIBOSOMAL RNA REGULATION IN HUMAN HEMATOPOIESIS". This 2-year grant (award date: Sep 1, 2024, completion date: Aug 31, 2026) will support research to quantify dynamics of ribosomal DNA (rDNA) activation...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA Program 93.837 - Cardiovascular Diseases Research) provides $549,796 to Cedars-Sinai Medical Center to conduct research focused on understanding how mutations in the TET2 and IDH2 genes associated with acute myeloid leukemia (AML) can impact cardiac metabolism and lead to cardiomyopathy and heart failure. The key research objectives are to: 1) Examine alterations in heart oxidative metabolism in response to TET2 or...
This $677,600 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to gain a mechanistic understanding of erythroid progenitor (EP) self-renewal, both in vitro and in vivo. The primary goals are to: Test the hypothesis that the BMI1/RING1B chromatin modulators regulate human self-renewing erythroblast (SRE) self-renewal through epigenetic control of transcription and cholesterol homeostasis. Test the hypothesis that...
This Project Grant award of $601,563 was provided by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), with a project period from September 1, 2024 to August 31, 2027. The award supports research to investigate the pathogenic roles and molecular mechanisms of the histone lysine demethylases KDM5A and KDM5B in the development and progression of heart failure, with a focus on hereditary cardiomyopathies like Lamin...
This federal Project Grant award, valued at $166,644.00 and awarded by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the functional and molecular consequences of aging and TET2 mutations on human hematopoietic stem cell responses to inflammatory cytokines like IL-1β. The research aims to provide a comprehensive understanding of how these factors alter inflammatory response pathways, leading...